Epitalon: what it is, what the research shows and where it stands with the FDA
Epitalon, also spelled epithalon, is a short lab-made peptide sold for anti-aging and sleep. It is not an FDA-approved drug, and the human evidence is small and comes mostly from one research group. In late October 2026 federal officials said they would, for now, allow licensed pharmacies to prepare it for individual patients. This page explains what that does and does not mean.
Information current as of November 10, 2026. Educational only. Confirm everything here with your own clinician before starting, stopping or changing any medication.
At a glance
What it is
A synthetic tetrapeptide of four amino acids: alanine, glutamate, aspartate and glycine (Ala-Glu-Asp-Gly).
What it is marketed for
Anti-aging, longevity and sleep. None of these is an FDA-approved use.
What the evidence shows
Mouse and cell studies, and a few small human studies, mostly from one group. No adequately sized human trial shows a clinical benefit.
Approval status
Not FDA-approved. A federal enforcement discretion policy currently allows licensed 503A pharmacies to prepare it for an individual patient under a prescription.
Main unknowns
Long-term safety, cancer risk, immune reactions to injected peptide and product quality. FDA reviewers found no human safety data.
Sports
Likely prohibited by WADA under its catch-all class for non-approved substances.
What it is
What epitalon is
Epitalon is a synthetic peptide made of four amino acids. It was designed by a Russian research group led by Vladimir Khavinson, based on the amino acid makeup of epithalamin, an extract of the pineal gland of animals. Epithalamin and epitalon are different substances. Epithalamin is a mixture taken from animal tissue. Epitalon is a single chemical made in a lab.
The pineal gland makes melatonin, which helps set the sleep and wake cycle. The idea behind epitalon is that it might restore pineal function that declines with age. It is also promoted for its supposed effect on telomerase, the enzyme that rebuilds the protective ends of chromosomes. Both ideas come mainly from lab and animal work, and neither has been shown to help people feel or live better.
Epitalon has never been an approved medicine in the United States, Canada, the United Kingdom or the European Union. It is also absent from the European and Japanese pharmacopeias.
The evidence
What the research shows, and its limits
Most of what is known about epitalon was published by Khavinson and colleagues. Their studies are small, and independent groups have rarely repeated them. That does not make the findings false. It means they have not been confirmed the way an approved drug’s benefits are.
Animal and cell studies
In mice, the group reported effects on spontaneous tumors and on lifespan in some strains. The FDA reviewers pointed out that these studies used a single fixed amount, small groups of animals, female mice only and short exposure, so they say little about safety or cancer risk. In 2025, a laboratory study in human cell lines reported longer telomeres after epitalon exposure, through telomerase or another repair route. Results in cultured cells do not show that the same thing happens, or helps, in a living person.
Human studies
The FDA found three published human studies. One was an older study in people with a hereditary eye disease, retinitis pigmentosa, in which epitalon was given by injection near the eye. It received an orphan drug designation in 2010 that was withdrawn in 2016.
A second was a randomized, placebo-controlled study of 75 women aged 40 to 50, mostly night-shift workers, which used a sublingual spray for 20 days. In the women who started with low levels of a melatonin breakdown product in the urine, that marker rose after treatment compared with placebo. The authors also reported better mood and physical condition by a measure the FDA said was not described. The study did not measure sleep, did not state how blinding was done, and was short and small. A related small study in shift workers looked at activity of body-clock genes.
A 2026 narrative review concluded that human evidence is limited to small physiological or biomarker studies and that no adequately powered randomized trial has established that epitalon treats anything. It called epitalon biologically active but clinically unproven. Individual results vary, and studies in different populations are not directly comparable.
Longevity and telomere claims
Websites that sell epitalon say it lengthens telomeres, slows aging, adds years of life and prevents disease. No human study shows any of these. The FDA did not evaluate anti-aging or longevity uses at all, because the nominations did not include enough information to do so.
Safety
Safety unknowns
FDA staff reviewed epitalon in 2026 and concluded there were no clinical data to support its safety in humans. They did not find repeat-dose toxicity studies or long-term cancer studies. Because the substance is reported to activate telomerase, and longer telomeres are generally linked to higher cancer risk, they raised a concern that long-term exposure could help abnormal cells escape normal aging. This is a theoretical concern, not a documented harm, and it is the reason the unknowns matter.
Injected peptides can also trigger immune reactions, particularly when the product contains clumped peptide or manufacturing impurities. The FDA could not rule this out. Product quality is a separate worry: epitalon has been found in products sold as research chemicals and in unlawful preparations, and those are not made to pharmacy standards.
The small human studies were not designed to detect uncommon or long-term harm. Reactions where an injection is given are possible with any injected product.
Call your physician or seek care for
- Swelling of the face, lips or throat, hives, or trouble breathing after a dose
- A spreading red, hot or painful area at an injection site, or fever
- Any new lump, unexplained weight loss or unusual bleeding
Who it is not for
Who should not use epitalon
Because human safety data are missing, the safest default is not to use it. These groups in particular should avoid it:
- Anyone with a current or past cancer, a strong family cancer history, or ongoing cancer screening concerns, given the telomerase question
- People who are pregnant, trying to conceive or breastfeeding. There are no human data
- Children and teenagers
- People with a history of serious allergic reactions to injected medicines or peptides
- People who want it for insomnia without first having the cause of the sleep problem checked. Sleep apnea, depression, medicines and shift work are common and treatable causes, and approved insomnia treatments exist
- Competitive athletes who are drug tested (see below)
Sports
WADA and anti-doping
The World Anti-Doping Agency prohibits, at all times, any drug with no current approval from a government health authority for human use. This class is called S0. Epitalon is not named in the text of the 2026 Prohibited List that I could read, but it appears to fall within the S0 wording because no regulator has approved it as a medicine. The FDA enforcement policy described below is not an approval and does not change that. An athlete who is tested should ask their anti-doping organization before taking it.
Regulatory status
Where epitalon stands with the FDA
Epitalon is not an FDA-approved drug. The compounded product is not evaluated by the FDA for safety, effectiveness or quality. A compounded drug is one a licensed pharmacist prepares for an individual patient. Pharmacies working under section 503A of the federal drug law are normally limited to certain bulk ingredients, and epitalon was not on that approved list.
The timeline
- May 2026: FDA staff wrote a review recommending that epitalon not be added to the 503A bulks list. They found a lack of evidence that it works for insomnia, the only use they evaluated, and no human safety data.
- July 24, 2026: FDA’s Pharmacy Compounding Advisory Committee voted to recommend adding epitalon anyway. A law firm summary reports the vote as 7 yes, 4 no and 1 abstention. The committee’s role is advisory only.
- October 28, 2026: The Department of Health and Human Services, which includes the FDA, announced an enforcement discretion policy for six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. The pharmacy trade group NCPA reported it on October 29 as an FDA action. The formal notice was published in the Federal Register on October 30, 2026, and comments were open for two weeks after that.
- Now: Formal rulemaking to add these peptides to the 503A bulks list is still pending. No end date was given for the enforcement discretion, and HHS said it may revisit the policy if a safety signal or quality problem appears.
In plain terms, federal officials currently do not intend to take action against licensed 503A pharmacies that prepare epitalon for an individual patient under a prescription and meet the policy’s conditions. Those conditions cover manufacturing quality, testing, labeling and adverse event reporting, and they limit epitalon to the acetate form as a subcutaneous or intramuscular injectable, given in intermittent courses. The policy itself is described as draft or interim, it creates no rights for anyone, and it is not approval. It could change.
What this does not mean
Enforcement discretion is not FDA approval, and it does not mean the FDA has found epitalon safe or effective. The FDA staff review from May 2026 found no human safety data.
Summit’s role
What Summit does with epitalon
Dr. Miranda decides whether epitalon fits you after your history and labs. If he prescribes it, a state-licensed pharmacy prepares it for you as a named patient. Summit does not dispense or sell it and keeps no stock in the office.
Nothing on this page promises a prescription. Given how little is known, Dr. Miranda may tell you that it is not a good fit, or that something better studied would serve your goal. See pricing for what the program includes, including labs.
Common questions
Questions people ask
Is epitalon FDA-approved?
No. It is not an FDA-approved drug, and the FDA has not evaluated the safety, effectiveness or quality of compounded epitalon. Since late October 2026, a federal enforcement discretion policy lets licensed 503A pharmacies prepare it for an individual patient under a prescription while formal rulemaking continues.
Does epitalon lengthen telomeres or slow aging in people?
That has not been shown. Telomere lengthening was reported in laboratory cell studies, and aging effects in animals. No human study has shown that epitalon slows aging or extends life, and the FDA raised a cancer concern about telomerase activation that has not been tested in people.
Does epitalon help sleep?
Not shown. The only use FDA reviewed was insomnia, and it found a lack of evidence. One small study found a rise in a melatonin breakdown product, but it did not measure sleep.
Why does so much of the research come from one group?
A Russian research group developed epitalon, and most published work comes from it and its collaborators. Independent confirmation is limited.
Is epitalon banned in sports?
It is not named in the 2026 WADA list text I could read, but it appears to fall under the S0 class for non-approved substances. Tested athletes should confirm with their anti-doping organization first.
Can Summit prescribe it?
Dr. Miranda decides after your history and labs. A state-licensed pharmacy would prepare any prescription. Summit does not dispense or sell epitalon, and nothing here is a promise of a prescription.
Sources
Where this comes from
All retrieved November 10, 2026.
- HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A and B. Federal Register FR Doc 2026-22192, October 30, 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, FR Doc. 2026-22192). Federal Register, October 30, 2026. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
- NCPA. FDA grants enforcement discretion to compounding six peptides. October 29, 2026. https://ncpa.org/newsroom/qam/2026/10/29/fda-grants-enforcement-discretion-compounding-six-peptides
- FDA. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: meeting page and materials. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- FDA. Evaluation of Epitalon-Related Bulk Drug Substances for Inclusion on the 503A Bulk Drug Substances List (briefing document for the advisory committee, May 2026). https://www.fda.gov/media/193345/download
- Jain A et al. Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. Int J Mol Sci 2026. https://pubmed.ncbi.nlm.nih.gov/42884164/
- Al-Dulaimi S et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025. https://pubmed.ncbi.nlm.nih.gov/40908429/
- Vanhee C et al. Identification of the small research tetra peptide Epitalon in two illegal pharmaceutical preparations. Drug Test Anal 2015. https://pubmed.ncbi.nlm.nih.gov/25535022/
- McDermott Will and Schulte. PCAC backs majority of peptides in two-day public meeting. July 27, 2026. https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/
- BakerHostetler. HHS Issues Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. October 28, 2026. https://www.bakerlaw.com/insights/hhs-issues-enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances/
- World Anti-Doping Agency. 2026 Prohibited List, class S0 (non-approved substances). Copy of the published List. https://pgtofindia.com/storage/app/anti_doping_link/pdf/Prohibited-List-2026.pdf
Confirm with your provider. This page is general education, not medical advice, and it does not diagnose or treat anything. Every medication carries risks and is not right for everyone. Medication is prescribed only after a physician evaluation determines it is appropriate for you. Individual results vary and no outcome is guaranteed. Information current as of November 10, 2026.
Next step
Start with a physician evaluation
Dr. Miranda reviews your history, medications, labs and goals before any decision about epitalon. As of November 10, 2026. Individual results vary.